Universiteit van die Oranje-Vrystaat - SAMJ Archive Browser

More documents

Recommendations

Info

KATETERSLU~TING VAN PATENTE DUKTUS ARTERIOSUS L br*, M ~ohl*, AD Bruwer Pediatri- Kar$ologie, Univexsiteit van die Oranje Vrystaat. Die duktus arteriosus verbind die proksirnale aorta net distaal tot die ontstaan van die linker subklaviese arterie met die. haof pulmonale arterie. Normaahveg siuit die duMus bme 48 uur M geboorte. Indien dit op 3 maande ouderdom nog nie SpOntane sluiting ondergaan het nie , word chirurgiese hitmg benodi n Altematief tot chirurgie Y wat onlsogs mmntlik geword %Lt, is die dui van die duktus deur middel van 'n prostese wat deur 'n ateter in die duktus arteriosus geplaas word. Indikasies: PasiEnte bo 6k. Duktus anato&es geskik. Normale ~ulmonale arterie drukke en weerstand. Die okklhie stelsel bestaan uit 'n toedienhgstelsel en die sluitingsapparaat self. Die sluitingsapparaat bestaan uit twee klein sambreeltjies wat aan rug aanmekaar geheg is. Die toedieningskateter met &e sluitingsapparaat daarin gelaai, word deur 'n skede vanaf die fernorale vena in posisie geplaas met die een sambreeltjie aan die aorta kant geopen en die ander binne in die hoof pulmonale arterieDie duktus arteriosus word hierdeur toegemaak en met stollings en latere endotekie vind voltedige afsluiting in die meerderheid van gevalle plaas. Tydens die prosedure word die posisie en onmiddellike effektiwite~t angiografies en eggokardiografies evalueer. Komph'kasies: Afhangend van die grootte van die duktus artenosus mag 'n tweegle inplasing nodig wees om 'n blywende lek op te hef. Hemohe as gevolg van 'n blywende lek Embolisasie van die sluitinsapparaat tydens die prosedure. Huidig is die prosedure slegs in enkele sentra beskikbaar en is duur. Dit spaar die pasiEnt 'n torakotomie met die narkose en chirurgiese risiko's daaraan verbonde. Hospitalisasie is aans~enlik korter en die pasient het geen borskas littekens, wat kosmeties voordelig is. E]TP Van der W&* JS Van ZyI Departement Plastiese en RekonstrnLtiewe c%hngie in sit* evaInasie Mn ehromarooafwgfrings in limfosiete na blootstelling aan UV-lig en Rontge~f-strale. SAMJ VOL. 80 7 DEC 1991 611 AN INVESTIGATION INTO THE BIOAVAXLABILITY OF TWO DEPOT HEDROROGESTERONE PRODUCTS 3 H Easmus5 G Groenewoud, H G Luus, F 0 Hiiller, P H Wessels Farmovs Ipstitute, University of the OFS, ~ ~ N T E I N ( . Dept of Obstetrics and Gynaecology, University of OFS). Medroxyprogesterone acetate (=A) is marketed in many countries in the depot form as a hormonal contraceptive with close to 100% efficacy. Following i.m. administration maximum plasma HPA levels are reached within a week with effective levels sustained for up to 14 wweeks when follow-up doses are usually administered. Contraception is effected by a combination of a decrease in cervical mucus, endometrial atrophy, LB and FSB suppression and no maturation of follicles. The study was performed to compare the bioavailabilit of HPA following i.m. admini tration of Petogen (Labethica) and Depo-Proved' (Upjohn) . Serum progesterone levels were also determined simultaneously. Bealthy, female volunteers, aged between 18 and 27 years, participated in this double-blind, single-dose, randomised parallel study (n = 28 per qroup). Starting 3 days after onset of the last menstrual period, blood was collected for baseline UPA and progesterone determinations. Thereafter 150mg UPA (lml) was administered and blood samples drawn forthnightly for 16 weeks for MPA and progesterone determinations. Blood sampling took place on the same time of the day. The mean and CV% of the pharmacokinetic variable AUD(2-16 weeks) of MPA were calcul ted as 11.85 [ng.h/ml) and 39.0% for DBPO-PRO-' (Upiphn) and 12.52 (ng.h/ll) and 28.2% for PETOGF3 (Pbethica). he geometric mean of the Vetogen /~e~o-hmvera~~ ratio was 110% and the 90% confidence interval 928 to 131%. One of the 56 subjects had a raised serum progesterone level at 10 weeks, indicative of ovulation. This is not surprising, since MPA, when administered in doses that confer contraception, does not necessarily inhibit ovulation. The pharmacokinetic da&a indicate "theraqutic equivalencen of Petogen and Depo- Provera . Their interchangeable use can be expected to result in comparable hormonal contraceptive potency and efficacy. PHARWACODYNAXICS OF THE MICROPARTICLE FORMULATION OF BUSERELIN N de la Re$, BE Meyer, F0 Miiller, HG Luus, B ~osenkranz" ~epartment of Pharmacology, university of the Orange Free State, oemf ontein, Republic of South Africa. Aoechst *G, Frankfurt, west Germany B' Buserelin is an analogue of luteinising hormone releasing hormone (LHRH). Administration of sufficient quantities of the drug with sufficient regularity reduces concentrations of the sex steroids to post-menopausal levels. Buserelin has recently been formulated in microparticles to provide a subcutaneous depot which will improve compliance and convenience for the patient. The aim of the study was to identify the optimum dose of microparticle buserelin which will prov'ide release of the drug sufficient to suppress ovarian function for 4 to 6 weeks (28 to 42 days). Thirty-two healthy female volunteers with normal f ollicular development and ovulation (progesterone level
612 SAMJ VOLW ?DES1991 . * The dose of 3.5 mg buserelin in this formulation is considered optimum since it provided sufficient relmae of the drug to suppress ovarian activity for 4 to 6 veeks. COMPARATIVE WOGLYCAEMIC EFFECTS OF TWO GLIBENCLAMIDE TMIET PRODUCI'S . . G Opnewoud, HG Luus, F0 Miilier, M van Dyk, f#i2z&&oola F v o Institute ~ for F%mnacology Drug ~evelopmek ruvemty of Or a ree State, Bloemfontem %emon m t e s a ~dizabeth The aim of this stu to compare the hypo ycaetp'c effect of two 25 mg bendan& a products [Semr&nil (Hoe&) and glihncgde (I.,enmt$ntb This was a single-blind, edose randomised, cross-over study followed bg a plaqbo pkw: %eke heal9 young male subjects cornpleted ot ghbencl~de phases an l0 sub'ects the placebo phase. Blood sampl# fo~ glucose assa were co&cted over-an 8h pew Subjects we* msmbe?t for 1% and received a conbnuou~ LV. &ion of 10% solut~oa Within 15 to 4.5 ho &er ingestion of either glibenclamide product, ten of the twelve ru&t~ eqerienced mild to moderate symp- of hypogl caemia The extent of these adverse events was e echvely controied by the ~~~~IIIUOUS ix. infusion of gh~eose. The hypoglycaemic symptoms lastaQ for 15 to 30 minutes and resolved without any additional administrahn of glucose. : , ' The mean values of r&vmt variables and 90% confidence intervals for the ratio "test/refmm are presented below: I - Variable ~emi-m@d Gliknclamide Placebo Confi- , . (HwefUO won) dence interval The mean decrease h Emin as compared to pIacebo was 33.6% and 33.7% for Semi-Dad and hnclamide, res vely. The corresponding mean de- in A&O-8h) was 7 .4ed 11.7%. respectwely. & -:F Ct A corn arable effect was observed for the 2 ppducts. e model app &m thus study employing @e constant infusion L of glucose may be succ@&&y used in future studies on hypogIycaemic ' - drugs of this type. 5 - h - -, d . HEMODINAMlEsE WlTCRAKSIES WSSEN PROPOFOL EN ESMOLOL J Diedericks*, CP Heibrt, FECL Hmdt, NJ Uys, J Briimmer. Departement Anest*, So& en Farmakologie, UOVS ' * Hoewel esmolol 'n ka halfhe het, dui voorlopige shuiies daarop dat daar onverwagte langd\vigc effekte van die middel is WaMeer dit in kombii met pr& gkbruik word Aangesien beide middek 1ewerMoedvloei vermhder, mag hul gekomb'meerde effek die oproiming van propofol vermin&. Hierdie stndie het die hemodinamiese effekte van bolus en volgehom infusies esmolol toegevoeg tot konstante infusie narkose met propofal, 11600k die moontlilre ondertiggende meganismes, ondersoek. Sewe Beagles is ond& met toestemming van die Etiese Komitee vir Proefdiere. Die dien L imhwmenteer onder halotaan narkose (O,7-1%) om globale- en str& linker ventrikel funksie te meet. Voor- en nalading van die hart d p h r met behulp van 'n ballon in die inferior vena cava cn Wtbare IS om die dalende aorta. Na iostrumentasie is halotam wrvang met propofol200 pg.kgl.min.-' en M 60 minute is kontroM&gs geneem en bloed getrek vir propofol en esmolol bloertLonsenMitk 'n Intrammeuse bolus esmolol MO m*', is gegee en'm geskfyf na 5, 10, 40 en 60 minute. 'U Tweede bolus esmolQJ (MO me1) g&g dew ~O@g.kg~slin-~ vir 10 minute is gegee en lesings geneem ap &sc&k tye as voorheen. Data is analiseer dew . . vir herbUlde mehgi. - . Pdsslag was deurentyd onveranderd Na die eerste bdus esmolol het Moeddrak verminder (-I-, P
Page 1 and 2: 598 SAMJ VOL. 80 7DES 1991 Universi
Page 3 and 4: 1 Dept Interne Geneeskunde 2 Dept N
Page 5 and 6: SURGICAL GLOW POWDER AND INTRAPERIT
Page 7 and 8: dl4 SAMJ V01 80 7 DES 1991 DIE ASHA
Page 9 and 10: 606 S W VOL 80 7 DES 1991 THE SERO-
Page 11 and 12: 608 SAMJ VOL 80 7 DES 1991 Die gemi
Page 13: 610 SAMJ VOL. 80 7DES 1991 Depastem
Page 17 and 18: 614 SAMJ VOL. 80 7 DES 1991 LT H#,
Page 19 and 20: 616 SAMJ VOL 80 7 DES 1991 V ~ ~ w
Page 21 and 22: 618 SAMJ VOL 80 7DES 1991 voorgeboo
Page 23 and 24: 620 SAMJ VOL. 80 7.DES 1991 Kerngen
Page 25 and 26: 622 SAW VOL. 80 7 DES 1991 BEPALING
Page 27 and 28: 624 SAMJ VOL. 80 7 DES 1991 A SENSl
Page 29: 26 VOL 80.7 DEC 1991 SAMJ Protein c

Universiteit van die Oranje-Vrystaat - SAMJ Archive Browser

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?